Communicating effectively with patients about vaccination

CCDR

Volume 49-7/8, July/August 2023: Enteric Diseases: A Major Health Problem in Canada

Systematic Review

Communicating effectively with patients about vaccination: A systematic review of randomized controlled trials

Chloé Desjardins1, Manon Denis-LeBlanc1,2,3, Christine Paquette Cannalonga1, Malek Rahmani1, Teresa A Gawargy1, Pierre-Marc Dion1, Jennifer Lacroix Harasym1, Salomon Fotsing1,2,3, Maria Cherba4, Nigèle Langlois5, Sylvain Boet1,3,6,7,8,9,10

Affiliations

1 Francophone Affairs, Faculty of Medicine, University of Ottawa, Ottawa, ON

2 Department of Family Medicine, University of Ottawa, Ottawa, ON

3 Institut du Savoir Montfort, Ottawa, ON

4 Department of Communication, Faculty of Arts, University of Ottawa, Ottawa, ON

5 Health Sciences Library, University of Ottawa, ON

6 Faculty of Education, University of Ottawa, Ottawa, ON

7 Departments of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON

8 Department of Innovation in Medical Education, University of Ottawa, Ottawa, ON

9 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON

10 Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, ON

Correspondence

sboet@uottawa.ca

Suggested citation

Desjardins C, Denis-LeBlanc M, Paquette Cannalonga C, Rahmani M, Gawargy TA, Dion P-M, Lacroix Harasym J, Fotsing S, Cherba M, Langlois N, Boet S. Communicating effectively with patients about vaccination: A systematic review of randomized controlled trials. Can Commun Dis Rep 2023;49(7/8):331–41. https://doi.org/10.14745/ccdr.v49i78a05

Keywords: communication, randomized controlled trials, vaccines, vaccine hesitancy

Abstract

Background: Good communication between healthcare professionals and their patients is essential to enlighten the benefits and risks of vaccination. Despite the availability of effective vaccines, reluctance prevails, sometimes fuelled by sub-optimal communication leading to a lack of trust. An evaluation of the effectiveness of a communication strategy for which healthcare professionals are trained has yet to be carried out.

Objective: Systematic review of studies with a randomized controlled trial (RCT) to define and evaluate the impact of healthcare professionals’ communication on patients’ vaccine adherence.

Methods: We performed a structured search on Medline, Embase, CENTRAL, PsycINFO and CINAHL. The studies selected include those involving healthcare professionals authorized to administer vaccines according to Canadian guidelines. Primary outcomes include vaccination rate or vaccine hesitancy rate.

Results: Nine articles were included. Five studies (n=5) reported intervention effectiveness according to vaccine adherence. The results are largely represented by parental vaccine hesitancy for human papillomavirus (HPV) or childhood vaccination, while three studies (n=3) target the general population. The risk of bias relative to the studies is either low (n=7) or of some concern (n=2).

Conclusion: The effectiveness of communication varies according to the studies and knowledge acquired through training. Future studies will need to examine communication with healthcare professionals in order to establish a consensus on optimal and appropriate training.

Introduction

Vaccination is effective in preventing many diseases and their serious forms. However, some patients are reluctant to be vaccinated, despite the potentially harmful consequences for their health and that of the population as a whole. This hesitancy stems from multiple, complex and sometimes interconnected factorsFootnote 1Footnote 2Footnote 3Footnote 4Footnote 5Footnote 6Footnote 7. Possible reasons include a lack of trust in healthcare professionals and institutions, healthcare professionals’ lack of patient communication skillsFootnote 4Footnote 5Footnote 7, or difficulties in navigating the sometimes contradictory information availableFootnote 1Footnote 2Footnote 3Footnote 5.

Physician-patient communication is defined in the literature as a key component of the therapeutic relationship, enabling the development of a bond of trust that leads to optimal careFootnote 5Footnote 7Footnote 8Footnote 9. The bond of trust is important when discussing vaccination, since the decision-making process has an impact on individual and community safetyFootnote 1. Given the importance of communication in healthcare decision-making, it is possible that a communication intervention with healthcare professionals could influence vaccine adherence. Given the coronavirus disease 2019 (COVID-19) pandemic and its repercussions, including the lack of educational resources in patient communication skills, a communication intervention is all the more important to address the limitations of healthcare institutions and mistrust of the COVID-19 vaccine. In the absence of intervention, current limitations may lead to mistrust of future vaccines in times of health crisis. The effectiveness of intervention has yet to be systematically evaluated.

Objectives

We conducted a systematic review of randomized controlled trials (RCTs) to define and evaluate the impact of healthcare professionals’ communication on patients’ vaccine adherence.

Methods

Protocol and registration

This systematic review was conducted in accordance with AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews) standardsFootnote 10 and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelinesFootnote 11. The protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42022330645).

Eligibility criteria

All RCTs in which participants were healthcare professionals authorized to administer vaccines (doctors, nurses, pharmacists and resident physicians) were eligible. We included studies in which communication on vaccine adherence was the main intervention. We excluded studies in which the healthcare professionals were medical, nursing or pharmaceutical students (not authorized to administer vaccines according to Canadian guidelines). We also excluded studies where the intervention was aimed at patients rather than healthcare professionals. Non-peer-reviewed articles, conference abstracts, letters, editorials and commentaries were not eligible.

Information sources

Two electronic search reviewsFootnote 12 were carried out, a Medline search strategy and a translation of the CINAHL RCT Filter search. MEDLINE® ALL via Ovid, Embase Classic + Embase via Ovid, Cochrane Central Register of Control Trials via Ovid, APA PsycINFO via Ovid and CINAHL via EBSCO were consulted.

Search

The search strategy (Supplemental material A) was developed by an information specialist with the research team and revised by a second information specialist as suggested in the Peer Review of Electronic Search Strategies (PRESS) guideFootnote 12. Eligibility criteria (Box 1) included no language or publication date limits. A filter for published RCTs was appliedFootnote 13. The search strategy was developed in Medline and then translated into the other databases. Key search concepts included MeSH terms related to vaccine adherence, healthcare professionals and communication. Only studies published and available in French or English were considered. The list of references cited in the included studies was also searched. The final list of included studies was reviewed by content experts to confirm their relevance.

Box 1: Search strategy eligibility criteria

Population: healthcare professionals authorized to administer vaccines (physicians, nurses, pharmacists and resident physicians)
Intervention: communication training for healthcare professionals to be used during vaccination consultations only
Comparison: a control group of healthcare professionals who received no communication intervention
Outcome: vaccine adherence, defined as receiving, intending to receive or being less reluctant to receive the series of disease-preventing vaccines according to the schedule suggested by the national immunization authority
Study date: no limit
Method: randomized controlled trial
Publication language: no initial limit
Publication date: no limit

Selection of studies

Studies were uploaded to a web-based software program, Covidence (version 2.0, Veritas Health Innovation, Melbourne, Australia)Footnote 14, and duplicates were removed. A pilot assessment tool, developed by the research team and tested on 30 randomly selected articles (Supplemental material B), was refined until subjectively acceptable agreement was established among the judges. Evaluation of each level of inclusion was carried out by pairs of independent reviewers, and conflicts were resolved by a third party.

Data extraction

A data extraction grid (Supplemental material C), developed by the research team, was tested by the same reviewers. Extraction was performed in duplicate by pairs of reviewers and consensus by a third party. Extracted data include publication characteristics (name of lead author, year of publication, data collection sites), study characteristics (objective, study design and context, number of healthcare professionals, outcomes), type of healthcare professional, intervention details and results.

Risk of bias inherent in each study

Pairs of reviewers assessed included studies for risk of bias according to the Risk of Bias Tool 2 for Randomized Controlled Trials (RoB 2)Footnote 15. The tool assesses the risk of bias attributed to study design, conduct and data reporting. For each area, a questionnaire is used to establish the level of risk as “low,” “some concern” or “high.” All areas must be predominantly low risk for the study to be considered reliableFootnote 15.

Data summary

A description of all included studies is presented in tables containing information on demographic, clinical and methodological quality. The results are summarized qualitatively, given the heterogeneity of the included studies.

Results

Selection of studies

The search identified 6,484 studies. After eliminating duplicates, 4,014 studies were assessed for eligibility, including 57 full-text articles, 48 excluded studies and 9 included studies (Figure 1).

Figure 1: PRISMA 2020Footnote a Flow Chart

Figure 1

Figure 1 - Text description

The figure shows the number of studies selected according to PRISMA guidelines. The search identified 6,484 studies. After eliminating duplicates, 4,014 studies were assessed for eligibility, including 57 full-text articles, 48 excluded studies and 9 included studies. The included studies (n=9) employed communication training in a variety of formats targeting different knowledge areas, including understanding the virus, how the vaccine works, assertive communication, effective recommendations and the patient perspective. The vaccination context was childhood diseases (n=2), pneumonia/influenza (n=3), or human papillomavirus (HPV) (n=4). Six studies looked at parental vaccine hesitancy and three at adult vaccine hesitancy.


Characteristics of selected studies

The included studies (n=9) employed communication training in a variety of formats targeting different knowledge areas, including understanding the virus, how the vaccine works, assertive communication, effective recommendations and the patient perspective. The vaccination context was childhood diseases (n=2), pneumonia/influenza (n=3), or human papillomavirus (HPV) (n=4). Six studiesFootnote 16Footnote 17Footnote 18Footnote 19Footnote 20Footnote 21 focused on parental vaccine hesitancy, and three on adult vaccine hesitancy Footnote 22Footnote 23Footnote 24. General characteristics are shown in Table 1.

Table 1: Key features of included studies
First author, year Country of data collection Type of study Background Sample size (n),
Age/sex (%)
Population Study duration and format Study objective(s) Risk of bias
Abdel-Qader, 2022Footnote 22 Jordan RCT Private practice of pharmacists and physicians 320 practitioners
Age: NR
Gender: 56 F vs. 43 M (intervention); 55 F vs. 45 M (control)
Doctors; pharmacists 16 online training sessions To study vaccine hesitancy and evaluate the effectiveness of a collaborative physician-pharmacist intervention to improve adult COVID-19 vaccine hesitancy. Some concern
Boom, 2010Footnote 16 United States RCT Community practices in paediatric and family medicine 189 practitioners
Age: NR
Gender: NR
Doctors One year; training one hour/day during lunch break To evaluate the effectiveness of a university-based continuing education intervention aimed at increasing childhood vaccination rates in paediatric and family medicine practices in a large metropolitan area. Low risk
Brewer, 2017Footnote 17 United States RCT Paediatric and family medicine clinics 30 clinics (number of practitioners NR)
Age: NR
Gender: NR
Doctors; nurses; unspecified (i.e. health professionals or authorized personnel) Four one-hour clinical training sessions To determine the effectiveness of training providers to improve their recommendations using presumptive announcements or participatory conversations for HPV vaccine coverage. Low risk
Dempsey, 2018Footnote 18 United States RCT Primary care practices 16 clinics/188 practitioners
Age: NR
Gender: NR
Doctors; nurses; unspecified (i.e. health professionals or authorized personnel) Series of two training sessions at team development meetings over six months To evaluate the effect of a 5-component HPV vaccine communication intervention conducted by healthcare professionals on adolescent HPV vaccination. Low risk
Gatwood, 2021Footnote 23 United States RCT Two regional community pharmacy chains 96 pharmacies (number of practitioners NR)
Age: NR
Gender: NR
Pharmacists Duration of training not reported; results were counted for a period of six months pre-intervention and post-intervention To evaluate the impact of a communication training program to improve pharmacist promotion of pneumococcal vaccine among high-risk adults in Tennessee. The aim was to make it easier for pharmacists to address each patient’s beliefs and attitudes toward vaccination, particularly adults with chronic illnesses that put them at high risk of invasive pneumococcal infection. Low risk
Gilkey, 2019Footnote 19 United States RCT Cook Children's outpatient clinics 25 clinics/77 practitioners
Age: NR
Gender: NR
Doctors One hour of clinical training To evaluate the efforts of a paediatric health system to improve HPV vaccination coverage among adolescent patients. The objectives were to assess the extent to which a quality improvement (QI) program reached clinics and physicians, and the program’s impact on HPV vaccination coverage. Low risk
Henrikson, 2015Footnote 20 United States RCT Outpatient paediatric and family medicine clinics 56 clinics/526 practitioners
Age: NR
Gender: 68 F vs. 32 M (intervention); 64 F vs. 36 M (control)
Doctors 45-minute training session; 10-month intervention To test whether a new communication intervention targeting physicians can improve physician confidence in communication and reduce vaccine hesitancy among mothers of infants. Some concern
Muñoz-Miralles, 2021Footnote 24 Spain RCT Urban and rural primary healthcare centres 57 practitioners
Age: NR
Gender: NR
Doctors; nurses Duration of training not reported; one-year intervention To determine the effectiveness of a brief intervention to increase influenza vaccination coverage compared with the usual advice in people who refuse it, and to record the main reasons for refusing to be vaccinated. Low risk
Szilagyi, 2021Footnote 21 United States RCT Paediatric primary care practices 48 clinics/234 practitioners
Age: NR
Gender: NR
Doctors Three 20–30 minute online training modules; 6-month intervention To evaluate the effect of online communication training for clinicians on missed HPV vaccination opportunities overall and during healthcare visits, acute and chronic illness visits, and on adolescent HPV vaccination rates. Low risk
Table 1 abbreviations

Abbreviations: COVID-19, coronavirus disease 2019; F, female; HPV, human papillomavirus; M, male; NR, not reported; RCT, randomized controlled trial


Summary of results

Among the studies (n=9) included, the effectiveness of the interventions varied greatly according to the training format (5 effectiveFootnote 17Footnote 18Footnote 20Footnote 21Footnote 24; 3 no significant differenceFootnote 16Footnote 19Footnote 20; 1 ineffective Footnote 23). A descriptive analysis of the communication adopted and its results are presented below. The measurement tools, primary outcomes and results with statistical significance are summarized in Table 2.

Table 2: Detailed results of included studies
First author, year Results measurement tool(s) Name of primary outcome(s) Conclusion of primary results
Abdel-Qader, 2022Footnote 22 Pre and post-intervention self-report survey assessing vaccine hesitancy and resistance from a physician’s perspective.

Pre and post-intervention self-report survey assessing vaccination status.

Pre and post-intervention self-report survey assessing knowledge, attitude and beliefs about COVID-19 vaccines.
The impact of collaborative physician-pharmacist training on COVID-19 vaccine hesitancy and resistance.

Proportion of patients vaccinated before and after intervention.
The proportions of COVID-19 vaccine hesitancy and resistance were significantly reduced (20.1% and 7.8% vs. 64.3% and 35.7%, p<0.05), including one month after training (3.3% vs. 11.1%). The proportion of subjects vaccinated increased considerably (51.6% vs. 0.0%) one month after training. There was no significant difference in the proportion of patients vaccinated between the intervention and control groups.
Boom, 2010Footnote 16 The Clinical Assessment Software Application (CASA) produced by the CDC (data entry and vaccination database). Immunization rate for children aged 12 to 23 months. There was no significant difference in the mean percentage of up-to-date vaccination for the control and intervention groups (19–23 months) (44% vs. 51%, p<0.05). After one year, there was a significant difference between the mean percentages of up-to-date vaccination for the control practices (41%) and the intervention practices (52%, p<0.05).
Brewer, 2017Footnote 17 Data on vaccine coverage, specialty, number of patients, patient gender and patient eligibility for state-funded vaccines according to the North Carolina Immunization Registry (NCIR). HPV vaccination rate in patients aged 11 to 17 years. Presumptive announcement training showed a significant increase in HPV vaccination initiation at 6 months in 11 and 12-year-old adolescents vs. the control group (5.4% difference, 95% CI: 1.1%–9.7%). There was no significant difference for the conversation training. There was no significant difference in the 13 to 17-year-olds in the two groups.
Dempsey, 2018Footnote 18 Vaccination data were extracted from each practice’s electronic medical record.

To ensure completeness, this data was supplemented by data from the Colorado Immunization Information System.
HPV vaccine series initiation (one dose). HPV vaccine initiation was significantly higher in adolescents in intervention practices (aOR: 1.46; 95% CI: 1.31–1.62) as was vaccine dose completion (aOR: 1.56; 95% CI: 1.27–1.92) compared to the control groups.
Gatwood, 2021Footnote 23 Vaccine distribution records (pneumococcus, influenza, herpes zoster) provided by Walgreens in the Memphis and Nashville, Tennessee areas.

Community vaccination beliefs and behaviours were compiled through an online survey facilitated by QuestionPro (Austin, Texas).
Increase in the rate of pneumococcal vaccination. Compared to the Nashville area, people in the Memphis area showed less agreement that vaccines are a good way to protect against disease (73.8% vs. 79.7%, p<0.05), indicating a lower likelihood of following vaccine recommendations (73.4% vs. 78.3%, p<0.05) and more concern about side effects (47.1% vs. 35.8%, p<0.0001). Between the 6-month periods in 2018 and 2019, pneumococcal vaccine rates administered (on all patients) decreased in both regions.
Gilkey, 2019Footnote 19 EMR to assess vaccine coverage.

Vaccination in patients aged 12 to 14 years using standardized EMR queries.
HPV coverage (minimum one dose) for:

1) Model 1 (an intention-to-treat analysis of all doctors randomly assigned to the intervention and control groups); 2) Model 2 (a sensitivity analysis that excluded 6 doctors (2 in the intervention group and 4 in the control group).
In the overall sample (Model 1), HPV vaccination coverage increased by 8.6 percentage points (intervention) and 6.4 percentage points (control). The treatment effect was not statistically significant according to a hierarchical linear model and an unstandardized coefficient (b) (b=0.023; SE=0.018; p<0.05). There was considerable variance in HPV vaccination coverage between physicians and clinics in Model 1, with the majority of the total variance lying with physicians (74%) vs. clinics (74%) vs. clinic level (14%).
Henrikson, 2015Footnote 20 Mother’s score on the “Parental attitudes to childhood vaccines” test.

Childhood vaccines by PACV percentage of mothers reluctant to vaccinate.

Six single-item self-efficacy questions on communicating with parents about childhood vaccines (email survey).
Maternal vaccine hesitancy at 6 months (dichotomous).

Maternal vaccine hesitancy at 6 months (ORDINAL measure).
The intervention had no effect on the mother’s vaccine hesitancy (p=0.78). Adjustment for baseline PACV score and race yielded similar results (OR: 1.22; 95% CI: 0.47–2.68; OR: 1 indicates no difference between the two groups).
Muñoz-Miralles, 2021Footnote 24 Electronic medical records. Vaccination rate. The intervention was effective overall (OR: 2.48 [1.61–3.82]; p<0.001) and in people aged 60 and over (in good health, OR: 2.62 [1.32–5.17]; and with risk factors, OR: 2.95 [1.49–5.79]). There was no statistically significant difference in the efficacy of the intervention in people under 60 with risk factors, or between different diseases.
Szilagyi, 2021Footnote 21 Electronic medical records. Percentage of office visits with a missed HPV vaccination opportunity for vaccine initiation.

Total number of missed opportunities for HPV vaccination.

Proportion of adolescents receiving HPV vaccination.
The rate of missed opportunities decreased in intervention vs. control practices by 6.8% (95% CI: 3.9–9.7) for HPV vaccination initiation. No significant difference was observed for subsequent vaccination.

The rate of missed opportunities decreased between the start of the study and the intervention period by 2.4% (95% CI: 1.2–3.5) in intervention vs. control practices.

For adolescents with at least one office visit during the intervention period, HPV vaccine initiation was 3.4% (95% CI: 0.6–6.2) higher in intervention vs. control practices. No significant difference was observed for subsequent vaccination.
Table 2 abbreviations

Abbreviations: aOR, adjusted odds ratio; CDC, Centers for Disease Control and Prevention; CI, confidence interval; COVID-19, coronavirus disease 2019; EMR, electronic medical records; HPV, human papillomavirus; PACV, Parental Attitudes on Childhood Vaccines score; OR, odds ratio; SE, standard error


Effectiveness of communication training

Effective training

First, we note some training courses that proved effective in the HPV context. These included educational resources and patient-adapted recommendations. Following a self-guided webinar and two group sessionsFootnote 18, the application of motivational interviewing during physician-patient interactions improved HPV vaccine adherence in adolescents. Similar training consisting of a webinar with three interactive modules and weekly encouragement to reveal common patient questions also improved vaccine adherenceFootnote 21.

We also observed that good physician-patient communication includes a good understanding of the virus, the vaccine and the reasons for vaccine hesitancy. The study by Muñoz-Miralles et al.Footnote 24 shows a positive effect in patients aged 60 and over following a brief standardized intervention in the context of influenza. Although this communication depended on a directive guide, doctors and nurses were encouraged to adapt their communication by using empirical evidence to address the reasons for vaccine hesitancy, gathered beforehand.

This example can be enriched by the intervention proposed by Abdel-Qader et al.Footnote 22, who integrated the patient-partner perspective into the training material. The training, organized in 16 virtual sessions in a private Facebook group, invited pharmacists to be trained by eight doctors and eight pharmacists. However, the training sessions particularly included testimonials from patients discussing their experiences with the health crisis and vaccination. The patient-partner perspective justified the importance of patient-adapted communication. This study shows a significant reduction in vaccine hesitancy and an increase in vaccination rates. It should be noted, however, that the self-reported results of this study may be biased.

Training courses based on assertive communication cannot be overlooked. Brewer et al.’s studyFootnote 17 demonstrated improved HPV vaccine adherence using an announcement, i.e., a vaccine recommendation given on the day of the consultation. The same study also evaluated the effectiveness of a conversation with the patient to present the vaccine for shared decision-making, but this intervention noted no significant difference.

Risk of relative and cross-study bias

Seven studiesFootnote 16Footnote 17Footnote 18Footnote 19Footnote 21Footnote 23Footnote 24 have low risk and two studies Footnote 20Footnote 22 are of some concern (see Table 3). A follow-up bias is present, as the healthcare professionals would have been aware of the result of randomizing to an intervention or control group. We consider this risk unavoidable, based on ethical considerations of informed consent, despite the fact that it may have had an impact on study results. The second biasFootnote 20Footnote 22 (measurement bias) is taken into account, since self-reported surveys were used, which can influence the validity of the results.

Table 3: Summary of risk of bias for included studies
Study - Cochrane RoB 2 Randomization bias Follow-up bias Attrition bias Measurement bias Evaluation and selection biases Overall risk of bias
Abdel-Qader, 2022Footnote 22 Low risk Some concern Low risk Some concern Low risk Some concern
Boom, 2010Footnote 16 Low risk Some concern Low risk Low risk Low risk Low risk
Brewer, 2017Footnote 17 Low risk Low risk Low risk Low risk Low risk Low risk
Dempsey, 2018Footnote 18 Low risk Some concern Low risk Low risk Low risk Low risk
Gatwood, 2021Footnote 23 Low risk Some concern Low risk Low risk Low risk Low risk
Gilkey, 2019Footnote 19 Low risk Some concern Low risk Low risk Low risk Low risk
Henrikson, 2015Footnote 20 Low risk Some concern Low risk Some concern Low risk Some concern
Muñoz-Miralles, 2021Footnote 24 Low risk Low risk Low risk Low risk Low risk Low risk
Szilagyi, 2021Footnote 21 Low risk Low risk Low risk Low risk Low risk Low risk
Table 1 abbreviations

Abbreviation: RoB 2, Risk of Bias Tool 2 for Randomized Controlled Trials


Discussion

Summary of levels of evidence

Randomized controlled trials evaluating the effectiveness of communication training for healthcare professionals are few in number and show mixed results in terms of vaccine adherence. Studies showing positive results have often adopted a communication approach aimed at formulating optimal recommendations and raising awareness of patients’ specific needs.

Interpretations

The effectiveness of interventions does not seem to depend simply on the presence of communication that adopts epidemiological and medical knowledge, but also on communication that is adapted to the patient, understanding the factors that influence the vaccination decision. The most effective interventionsFootnote 24Footnote 25 focused on HPV and targeted parents of minor patients. These studies have potentially been built on a better understanding of parental vaccine hesitancy, since the reasons for vaccine hesitancy and HPV have previously been addressed through research, improved communication and the development of quality recommendationsFootnote 25. An adapted intervention, such as motivational interviewingFootnote 18, is consequently viewed favourably in the literature and by healthcare professionalsFootnote 6Footnote 26Footnote 27Footnote 28. Infant vaccination (excluding HPV), on the other hand, seems to require more research, as indicated by studies by Brewer et al. and Henrikson et al.Footnote 17Footnote 20.

Contradictory results on the effectiveness of communication training can raise questions about the wider potential role of communication skills. In fact, communication in the therapeutic relationship is not limited exclusively to the transfer of medical knowledge about vaccination in clinical consultations. Both parties—the healthcare professional and the patient—are also influenced by societal communication, including socio-political and cultural factors that may be disseminated by public health authorities and popular rhetoric. In the case of HPV, linked to the sensitive subject of adolescent sexuality and genderFootnote 29Footnote 30Footnote 31, several socio-political factors have prompted a change in the public’s approach to vaccinationFootnote 32. Social and medical perception seems to depend on multiple variables including ideology, customs, understanding of health, collective responsibility, trust and accessibility to healthcareFootnote 33.

Given the complexity of vaccine hesitancy, we would like to hypothesize that effective communication must take into account the above variables. The literature points to the inefficiency of a universal algorithm. In 2015, a systematic review on vaccine hesitancy demonstrated the need for a call for strategies tailored to the target population, the reasons for hesitancy and their contextFootnote 34. We note in particular that effective studies tended to form recommendations with subjectivity according to the patient’s concerns, but the integration of all these variables remains to be applied to establish a bond of trust with patients. Further socio-culturally adapted communication interventions would be needed to study this topic.

Limitations

There are several limitations to note. Other diversified studies would have enabled a better scope of conclusions, as well as a meta-analysis to understand the relationship between different groups of healthcare professionals, different diseases and vaccines, and then different communication training. Studies may be missing given the broad scope of the search strategy, the exclusion of articles published neither in English nor French, and the fact that only studies involving healthcare professionals authorized to administer the vaccine in Canada were included. Some studies also included different clinical locations and determining variables that may have been ignored or absent, such as regional infection rates, the context of the intervention (e.g. a national or regional vaccination program) and the demographics of specific patient groups. RCTs only were included in the study because of their rigorous methodology. It would also have been possible to include cohort studies with the same type of intervention.

Conclusion

The effectiveness of vaccination-related communication varies according to the studies and knowledge acquired through training. This systematic review confirms the need for studies that focus on communication with healthcare professionals to build consensus around optimal, tailored training that increases trust in healthcare institutions. There is thus a need for studies that take into account initiatives that include the patient perspective in communication with healthcare professionals.

Author's statement

  • CD — Participation in study design, writing–original draft, data acquisition and evaluation, data analysis, writing–revision and editing, final approval
  • MD-L — Participation in study design, writing–revision and editing, final approval
  • CPC — Data acquisition and evaluation, writing–revision and editing, final approval
  • MR — Data acquisition and evaluation, writing–revision and editing, final approval
  • TAG — Data acquisition and evaluation, writing–revision and editing, final approval
  • P-MD — Data acquisition and evaluation, writing–revision and editing, final approval
  • JLH — Participation in study design, writing–revision and editing, final approval
  • SF — Participation in study design, writing–revision and editing, final approval
  • MC — Participation in study design, writing–revision and editing, final approval
  • NL — Search strategy development, writing–revision and editing, final approval
  • SB — Participation in study design, development of search strategy, data analysis, writing–revision and editing, final approval

Competing interests

No conflicts of interest have been declared.

Funding

This systematic review was funded by the Public Health Agency of Canada.

Supplemental material

These documents are available in the Supplemental material file.

Supplemental material A: Search strategy

Supplemental material B: Effective communication strategies

Supplemental material C: Data extraction grid

References

Footnote 1

Borah P, Hwang J. Trust in Doctors, Positive Attitudes, and Vaccination Behavior: The Role of Doctor–Patient Communication in H1N1 Vaccination. Health Commun 2022;37(11):1423–31. https://doi.org/10.1080/10410236.2021.1895426

Return to footnote 1 referrer

Footnote 2

Statistics Canada. COVID-19 vaccine willingness among Canadian population groups. StatCan; Ottawa, ON: 2021. [Accessed 2021 Sep 13]. https://www150.statcan.gc.ca/n1/pub/45-28-0001/2021001/article/00011-eng.htm

Return to footnote 2 referrer

Footnote 3

Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EClinicalMedicine 2021;40:101113. https://doi.org/10.1016/j.eclinm.2021.101113

Return to footnote 3 referrer

Footnote 4

Gualano MR, Olivero E, Voglino G, Corezzi M, Rossello P, Vicentini C, Bert F, Siliquini R. Knowledge, attitudes and beliefs towards compulsory vaccination: a systematic review. Hum Vaccin Immunother 2019;15(4):918–31. https://doi.org/10.1080/21645515.2018.1564437

Return to footnote 4 referrer

Footnote 5

Cataldi JR, O’Leary ST. Parental vaccine hesitancy: scope, causes, and potential responses. Curr Opin Infect Dis 2021;34(5):519–26. https://doi.org/10.1097/QCO.0000000000000774

Return to footnote 5 referrer

Footnote 6

Braun C, O’Leary ST. Recent advances in addressing vaccine hesitancy. Curr Opin Pediatr 2020;32(4):601–9. https://doi.org/10.1097/MOP.0000000000000929

Return to footnote 6 referrer

Footnote 7

Attwell K, Betsch C, Dubé E, Sivelä J, Gagneur A, Suggs LS, Picot V, Thomson A. Increasing vaccine acceptance using evidence-based approaches and policies: insights from research on behavioural and social determinants presented at the 7th Annual Vaccine Acceptance Meeting. Int J Infect Dis 2021;105:188–93. https://doi.org/10.1016/j.ijid.2021.02.007

Return to footnote 7 referrer

Footnote 8

Petrocchi S, Iannello P, Lecciso F, Levante A, Antonietti A, Schulz PJ. Interpersonal trust in doctor-patient relation: evidence from dyadic analysis and association with quality of dyadic communication. Soc Sci Med 2019;235:112391. https://doi.org/10.1016/j.socscimed.2019.112391

Return to footnote 8 referrer

Footnote 9

Matusitz J, Spear J. Effective doctor-patient communication: an updated examination. Soc Work Public Health 2014;29(3):252–66. https://doi.org/10.1080/19371918.2013.776416

Return to footnote 9 referrer

Footnote 10

Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. https://doi.org/10.1136/bmj.j4008

Return to footnote 10 referrer

Footnote 11

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71

Return to footnote 11 referrer

Footnote 12

McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol 2016;75:40–6. https://doi.org/10.1016/j.jclinepi.2016.01.021

Return to footnote 12 referrer

Footnote 13

Canadian Agency for Drugs and Technologies in Health. CADTH Search Filters Database. [Accessed 2022 Jan 20]. https://searchfilters.cadth.ca/

Return to footnote 13 referrer

Footnote 14

Veritas Health Innovation. Covidence Systematic Review Software. [Accessed 2021 Sep 20]. www.covidence.org

Return to footnote 14 referrer

Footnote 15

Cochrane Collaboration. Assessing Risk of Bias in Included Studies | Cochrane Bias. https://handbook-5-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm

Return to footnote 15 referrer

Footnote 16

Boom JA, Nelson CS, Kohrt AE, Kozinetz CA. Utilizing peer academic detailing to improve childhood immunization coverage levels. Health Promot Pract 2010;11(3):377–86. https://doi.org/10.1177/1524839908321487

Return to footnote 16 referrer

Footnote 17

Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements versus conversations to improve HPV vaccination coverage: A randomized trial. Pediatrics 2017;139(1): e20161764. https://doi.org/10.1542/peds.2016-1764

Return to footnote 17 referrer

Footnote 18

Dempsey AF, Pyrznawoski J, Lockhart S, Barnard J, Campagna EJ, Garrett K, Fisher A, Dickinson LM, O’Leary ST. Effect of a health care professional communication training intervention on adolescent human papillomavirus vaccination a cluster randomized clinical trial. JAMA Pediatr 2018;172(5):e180016. https://doi.org/10.1001/jamapediatrics.2018.0016

Return to footnote 18 referrer

Footnote 19

Gilkey MB, Parks MJ, Margolis MA, McRee AL, Terk JV. Implementing evidence-based strategies to improve HPV vaccine delivery. Pediatrics 2019;144(1):e20182500. https://doi.org/10.1542/peds.2018-2500

Return to footnote 19 referrer

Footnote 20

Henrikson NB, Opel DJ, Grothaus L, Nelson J, Scrol A, Dunn J, Faubion T, Roberts M, Marcuse EK, Grossman DC. Physician communication training and parental vaccine hesitancy: A randomized trial. Pediatrics 2015;136(1):70–9. https://doi.org/10.1542/peds.2014-3199

Return to footnote 20 referrer

Footnote 21

Szilagyi PG, Humiston SG, Stephens-Shields AJ, Localio R, Breck A, Kelly MK, Wright M, Grundmeier RW, Albertin C, Shone LP, Steffes J, Rand CM, Hannan C, Abney DE, McFarland G, Kominski GF, Seixas BV, Fiks AG. Effect of Training Pediatric Clinicians in Human Papillomavirus Communication Strategies on Human Papillomavirus Vaccination Rates: A Cluster Randomized Clinical Trial. JAMA Pediatr 2021;175(9):901–10. https://doi.org/10.1001/jamapediatrics.2021.0766

Return to footnote 21 referrer

Footnote 22

Abdel-Qader DH, Hayajneh W, Albassam A, Obeidat NM, Belbeisi AM, Al Mazrouei N, Al-Shaikh AF, Nusair KE, Al Meslamani AZ, El-Shara AA, El Sharu H, Mohammed Ebaed SB, Mohamed Ibrahim O. Pharmacists-physicians collaborative intervention to reduce vaccine hesitancy and resistance: A randomized controlled trial. Vaccine X 2022;10:100135. https://doi.org/10.1016/j.jvacx.2021.100135

Return to footnote 22 referrer

Footnote 23

Gatwood J, Renfro C, Hagemann T, Chiu CY, Kapan S, Frederick K, Hohmeier KC. Facilitating pneumococcal vaccination among high-risk adults: impact of an assertive communication training program for community pharmacists. J Am Pharm Assoc (2003) 2021;61(5):572–580.e1. https://doi.org/10.1016/j.japh.2021.04.011

Return to footnote 23 referrer

Footnote 24

Muñoz-Miralles R, Bonvehí Nadeu S, Sant Masoliver C, Martín Gallego A, Gómez del Canto J, Mendioroz Peña J, Bonet Esteve AM. Effectiveness of a brief intervention for acceptance of influenza vaccine in reluctant primary care patients. Gac Sanit 2022;36(5):446–51. https://doi.org/10.1016/j.gaceta.2021.01.002

Return to footnote 24 referrer

Footnote 25

Kornides ML, McRee AL, Gilkey MB. Parents Who Decline HPV Vaccination: Who Later Accepts and Why? Acad Pediatr 2018;18 2S:S37–43. https://doi.org/10.1016/j.acap.2017.06.008

Return to footnote 25 referrer

Footnote 26

Mbaeyi S, Fisher A, Cohn A. Strengthening Vaccine Confidence and Acceptance in the Pediatric Provider Office. Pediatr Ann 2020;49(12):e523–31. https://doi.org/10.3928/19382359-20201115-02

Return to footnote 26 referrer

Footnote 27

Castillo E, Patey A, MacDonald N. Vaccination in pregnancy: challenges and evidence-based solutions. Best Pract Res Clin Obstet Gynaecol 2021;76:83–95. https://doi.org/10.1016/j.bpobgyn.2021.03.008

Return to footnote 27 referrer

Footnote 28

Rauh LD, Lathan HS, Masiello MM, Ratzan SC, Parker RM. A Select Bibliography of Actions to Promote Vaccine Literacy: A Resource for Health Communication. J Health Commun 2020;25(10):843–58. https://doi.org/10.1080/10810730.2021.1878312

Return to footnote 28 referrer

Footnote 29

Casper MJ, Carpenter LM. Sex, drugs, and politics: the HPV vaccine for cervical cancer. Sociol Health Illn 2008;30(6):886–99. https://doi.org/10.1111/j.1467-9566.2008.01100.x

Return to footnote 29 referrer

Footnote 30

Audisio RA, Icardi G, Isidori AM, Liverani CA, Lombardi A, Mariani L, Mennini FS, Mitchell DA, Peracino A, Pecorelli S, Rezza G, Signorelli C, Rosati GV, Zuccotti GV. Public health value of universal HPV vaccination. Crit Rev Oncol Hematol 2016;97:157–67. https://doi.org/10.1016/j.critrevonc.2015.07.015

Return to footnote 30 referrer

Footnote 31

Vorsters A, Arbyn M, Baay M, Bosch X, de Sanjosé S, Hanley S, Karafillakis E, Lopalco PL, Pollock KG, Yarwood J, Van Damme P. Overcoming barriers in HPV vaccination and screening programs. Papillomavirus Res 2017;4:45–53. https://doi.org/10.1016/j.pvr.2017.07.001

Return to footnote 31 referrer

Footnote 32

Gilkey MB, McRee AL. Provider communication about HPV vaccination: A systematic review. Hum Vaccin Immunother 2016;12(6):1454–68. https://doi.org/10.1080/21645515.2015.1129090

Return to footnote 32 referrer

Footnote 33

Peters MD. Addressing vaccine hesitancy and resistance for COVID-19 vaccines. Int J Nurs Stud 2022;131:104241. https://doi.org/10.1016/j.ijnurstu.2022.104241

Return to footnote 33 referrer

Footnote 34

Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ; SAGE Working Group on Vaccine Hesitancy. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine 2015;33(34):4180–90. https://doi.org/10.1016/j.vaccine.2015.04.040

Return to footnote 34 referrer

Page details

Date modified: